Phase-III-Studie

Beyond's analysis on Phase-III-Studie

• 2026-10-02 — Hansoh Pharma's Phase III data showing 19.3% weight loss with its dual GLP-1/GIP agonist positions it as a formidable contender in the fast-growing obesity therapeutics market

Recent news mentioning Phase-III-Studie

• 2026-10-02 — 19,3 % Gewichtsverlust in Woche 48: Daten der Phase-III-Studie zu Olatorepatid, Hansohs dualem, biased GLP-1/GIP-Agonisten, auf der EASD-Tagung vorgestellt

Appears alongside

• Gewichtsverlust
• Woche
• Olatorepatid
• Hansohs
• GLP-1/GIP-Agonisten

Browse the full archive →